New article: Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma https://t.co/F3fd7c259t #MMSM #MultipleMyeloma #hematology https://t.co/efeTU37nwJ
RT @KarunNep: July 1st: -Survived the first day of #imresidency (courtesy of my amazing chiefs @jmcchiefs, residents and co-interns @Jacob…
RT @KarunNep: July 1st: -Survived the first day of #imresidency (courtesy of my amazing chiefs @jmcchiefs, residents and co-interns @Jacob…
RT @KarunNep: July 1st: -Survived the first day of #imresidency (courtesy of my amazing chiefs @jmcchiefs, residents and co-interns @Jacob…
RT @KarunNep: July 1st: -Survived the first day of #imresidency (courtesy of my amazing chiefs @jmcchiefs, residents and co-interns @Jacob…
RT @KarunNep: July 1st: -Survived the first day of #imresidency (courtesy of my amazing chiefs @jmcchiefs, residents and co-interns @Jacob…
July 1st: -Survived the first day of #imresidency (courtesy of my amazing chiefs @jmcchiefs, residents and co-interns @JacobiHosp) ✅ -1st author paper published ✅: Here we summarized the mgmt of toxicity of drugs Selinexor and Belantamab. https://t.co/k